NABLA

Alexandre Lebrun had already sold two AI companies before Nabla. He built VirtuOz, which Nuance bought in 2013.

Then he built Wit.ai, a voice AI tool that Meta snapped up in 2015. In 2018 he teamed up with Delphine Groll, Martin Raison, and Laurent Landowski to start Nabla in Paris.

The first product was a digital health app aimed at women. It was fine.

It was not a rocket ship. The real turn came when large language models got good enough to follow a messy real conversation.

Lebrun pivoted the team to build Nabla Copilot, an assistant that turns a doctor visit into a finished note.

Here is the problem Nabla solves. Doctors spend hours every day typing up notes after seeing patients.

That time is unpaid, exhausting, and a huge reason so many of them burn out. Nabla Copilot listens to the visit and drafts the clinical note in seconds.

The doctor checks it and moves on. Health systems and clinics pay Nabla a subscription for each clinician who uses it.

More doctors using it means more revenue. That is basically it.

Nabla Copilot is the whole show. It listens to a patient visit, in person or over video, and produces a structured clinical note.

It handles multiple languages and specialties. It plugs into the electronic health record so the note lands where the doctor already works.

Newer versions push toward agentic features, meaning the AI handles more of the follow-up tasks around a visit, not just the writing.

Nabla leaned hard into being the specialist. Plenty of AI scribes exist now.

Nabla's pitch is that it was built by AI people who spent years on conversational systems, not a general chatbot bolted onto healthcare. It also went where the pain was worst, partnering with big provider groups drowning in admin work.

Neighborhood Healthcare, a California network, rolled out Nabla across its clinics in 2025. The plan is simple.

Save each doctor an hour a day and the product sells itself.

The AI scribe market got crowded fast. Abridge raised huge rounds.

Microsoft owns Nuance and its DAX Copilot. Every electronic records company wants a piece.

Nabla is smaller and European in a market where the biggest money is American. The other hard part is trust.

An AI writing medical notes cannot make things up, because a fake symptom in a chart is dangerous. Nabla has to prove its notes are accurate every single time or the whole thing falls apart.

Cathay Innovation has been the anchor, leading Nabla's Series A in 2022 and its Series B in 2024. The June 2025 Series C brought in bigger names.

Highland Europe and DST Global joined, along with Tony Fadell's Build Collective. Fadell is the guy who led the team behind the iPod and founded Nest, so his backing signals this is a serious bet.